Adlai Nortye(ANL)

Focus: Adlai Nortye is a newly public (2023) biotechnology company headquartered in North Brunswick, NJ, focused on cancer and metabolic disease treatments with an early-stage pipeline.

Oncology Metabolic Diseases

Profile data last refreshed 4h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Adlai Nortye

AI assessmentNot Hiring

No open roles listed right now. Follow Adlai Nortye to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

E7046

Neoadjuvant Therapy in Rectal Cancer

Phase 1

Clinical Trials (1)

NCT03152370Preoperative Radiotherapy and E7046 in Rectum Cancer

Phase 1

Help build intelligence for Adlai Nortye

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to join a newly public company at the ground floor with potential for significant equity upside during growth phase
Focused pipeline in high-value therapeutic areas (oncology and metabolic diseases) with multiple shots on goal across solid tumors
Early-stage company culture with potential for rapid career advancement and impact on drug development strategy

Watch Out For

Zero active job openings currently listed, suggesting minimal immediate hiring or uncertain growth trajectory
All programs in Phase 1 or early development (7 Phase 1 vs. 1 Phase 3) with significant clinical and regulatory risk ahead
No revenue, published data, or approved products to validate business model or provide job stability

Generated by Claude from Adlai Nortye's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

pelareorep

Advanced or Metastatic Breast Cancer

Phase 1

Clinical Trials (1)

NCT05519059Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

Phase 1

AN4005

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT04999384First in Human, Dose Escalation Study of AN4005

Phase 1

AN0025

Esophageal Cancer

Phase 1

Clinical Trials (3)

NCT05358691A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Phase 1

NCT04975958Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Phase 1

NCT05191667AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

Phase 1

AN9025

Solid Tumors

Phase 1

Clinical Trials (1)

NCT07252479Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

Phase 1

buparlisib

Head and Neck Cancer

Phase 3

Clinical Trials (1)

NCT04338399The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 8 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

8 pipeline

Marketed

Pipeline